COMPREHENSIVE MODELING AND SIMULATIONS FOR...
Transcript of COMPREHENSIVE MODELING AND SIMULATIONS FOR...
BIOVIA DISCOVERY STUDIO® 2018COMPREHENSIVE MODELING AND SIMULATIONS
FOR LIFE SCIENCES
ACCURATELY PREDICT LIGAND
BINDING ENERGIES
Drug discovery is a multi-objective optimization. Drug discovery is a multi-objective optimization. Scientists have to optimize both biochemical potency and characteristics such as ADME and toxicity. The latest release of BIOVIA’s predictive science applica-tion, Discovery Studio®, continues the evolution of new free energy prediction simulations. Built on BIOVIA Pipeline Pilot™, Discovery Studio® is uniquely positioned as the most comprehensive, collaborative modeling and simulation application for Life Sciences discovery research.
DISCOVERY STUDIO 2018Part of the 2018 BIOVIA product release series, Discovery Studio 2018 continues to deliver key new Small Molecule simulations and Antibody humanization enhancements.
NEW AND ENHANCED SCIENCE• New! Accurately predict relative ligand binding energy for a congeneric ligand series using the new free energy perturbation (FEP) method
- Pair Ligands for FEP: A new command to pair two ligands for a relative FEP calculation - Generate Ligand Pairs for FEP: A new protocol to plan a set of relative FEP calculations to span a dataset of congeneric ligands
- Set Up Relative FEP Calculations: A new protocol to gen-erate multiple simulation systems for performing FEP calculations - Free Energy Perturbation (FEP): A new protocol to run multiple FEP simulations in serial, parallel, or on grids using NAMD. This replaces the Free Energy Perturbation (NAMD™1) protocol in 2017 R2 that could only run a single system - Collate FEP Simulation Results: A new protocol to integrate and analyze results from multiple relative FEP simulations and calculate absolute free energy values
• New! Type molecules using CGenFF and charmm36 for CHARMm™ or NAMD1-based simulations with the MATCH™ typing engine from the Brooks Lab
• New! Predict stabilizing humanized residue mutations: Predict mutations to make an antibody more human-compatible with-out losing specificity of antigen binding
- Calculate Mutation Energy (Stability): An option has been added to allow mutations to be specified using a sequence alignment. This facilitates trialing large numbers of muta-tions, and is particularly useful in conjunction with the suggested mutation alignments created by the new Predict Humanizing Mutations protocol - A new Create Humanization Database example protocol has been created to process data for use in the Predict Human-izing Mutations protocol - The Prepare Germline Sources example protocol has been enhanced to optionally save each annotated gene sequence to a separate file. This allows a specific gene to be selected for use in the Predict Humanizing Mutations protocol
• New! CHARMM PBEQ ,4,5 Poisson-Boltzmann-based electro-static solver: The DelPhi electrostatics component has been replaced with a CHARMm PBEQ Solver, based on the CHARMm PBEQ module to solve the Poisson-Boltzmann equation. It includes a number of new features and improvements:
- A better definition of the Poisson-Boltzmann grid, based on the grid spacing and distance from boundary - An orthorhombic grid box to calculate the potential of mol-ecules more efficiently - The electrostatic potential values and energies are reported in kcal/mol.e and kcal/mol - The focusing center can be set up automatically as the center of a selected group of atoms, instead of the carte-sian coordinates - Calculations can now be performed for membrane environ-ments, either as a planar slab (uniform dielectric constant) or as multiple regions (cf. low dielectric hydrophobic region and lipid head group regions)
• Enhanced! Several of the pharmacophore protocols have been redesigned to improve performance and scalability for parallel computing, including:
- Ligand Pharmacophore Mapping - Screen Library - Receptor Ligand Pharmacophore Generation - Ligand Profiler
Figure 1: Network map showing the relative similarities in a congeneric set of ligands.
Figure 2: Sequence hotspot map showing humanization hotspots according to germline analysis. At each position, detailed amino acid options are presented via ‘logo plots’.
hsp90_5
hsp90_4
hsp90_9
hsp90_3
hsp90_1
hsp90_2
hsp90_34
hsp90_40
hsp90_30hsp90_29
hsp90_18
hsp90_48
hsp90_51hsp90_12
hsp90_7
0.67
0.67
0.67
0.82
0.82
0.82
0.74
0.670.67
0.61
0.61
0.610.9
0.9
• New! A Post-Process Screen Library Results example protocol has been added to assist with post-processing large Screen Library results
• Update! TopKat® QMRF Reports6: All remaining extensible TopKat Toxicity Models QSAR Model Report Format (QMRF) reports have been accepted and published on the European Commission Joint Research Center (JRC)
QMRF # Title
Q17-33-0048 BIOVIA toxicity prediction model-acute fish toxicity
Q17-31-0047 BIOVIA toxicity prediction model-acute toxicity to Daphnia
Q17-410-0037 BIOVIA toxicity prediction model-Ames Mutagenicity
Q17-49-0046 BIOVIA toxicity prediction model-eye irritant vs non-irritant
Q17-49-0044 BIOVIA toxicity prediction model-mild vs moderate eye irritant
Q17-49-0045 BIOVIA toxicity prediction model-moderate vs severe eye irritant
Q17-412-0052BIOVIA toxicity prediction model-NTP carcinogenicity call (female mouse)
Q17-412-0051 BIOVIA toxicity prediction model-NTP carcinogenicity call (female rat)
Q17-412-0050BIOVIA toxicity prediction model-NTP carcinogenicity call (male mouse)
Q17-412-0039 BIOVIA toxicity prediction model-NTP carcinogenicity call (male rat)
Q17-416-0041 BIOVIA toxicity prediction model-prenatal developmental toxicity
Q17-42-0038 BIOVIA toxicity prediction model-rat oral LD50
Q17-46-0042 BIOVIA toxicity prediction model-skin sensitiser vs non sensitiser
Q17-46-0043 BIOVIA toxicity prediction model-weak vs strong sensitiser
QMRF # Title
Q17-412-0049BIOVIA toxicity prediction model-weight of evidence rodent carcinogenicity
Q17-412-0008 BIOVIA toxicity prediction model-mouse carcinogenic potency TD50
Q17-23a-0009 BIOVIA toxicity prediction model-aerobic biodegradability
Q17-412-0007 BIOVIA toxicity prediction model-rat carcinogenic potency TD50
Q17-414-0006BIOVIA toxicity prediction model-rat chronic lowest observed adverse effect level (LOAEL)
Q17-41-0005 BIOVIA toxicity prediction model-rat inhalational LC50
Q17-44-0004BIOVIA toxicity prediction model-skin irritancy (mild vs moderate/severe)
Q17-44-0003 BIOVIA toxicity prediction model-skin irritancy (moderate vs severe)
Q17-44-0002 BIOVIA toxicity prediction model-skin irritancy (none vs irritant)
• Update! The TopKat Detailed Report now contains additional information to improve traceability and reproducibility
• Update! The Detailed Report in the Toxicity Prediction (Exten-sible) protocol has been modified to improve readability and interpretability
PARTNER SCIENCE• CHARMm: Incorporates the latest release of the academic
CHARMM, version c42b12
• NAMD: Distributed with the CPU edition, version 2.12• MODELER: Incorporates the latest release of the academic
MODELLER, version 9.197 • BLAST+: The BLAST+ version in Discovery Studio has been
updated to 2.7
DATABASES• ANTIBODY has been updated to include the latest antibody
template structures from the PDB (based on PDB release August 2017)
• BLAST databases updated for PDB_nr95, PDB, SwissProt, UniRef90, NR based on corresponding public databases as of March 2017
• The RCSB ligand database was updated for the RCSB Structure Search protocol (November 2017, 25,392 entries)
COMPATIBILITYDiscovery Studio 2018 is built on and supports the latest release of BIOVIA Pipeline Pilot, version 2018• 64-bit Support: Discovery Studio executables are now all
native 64-bit on both Linux and Windows
Figure 3: Comparison in CATALYST pharmacophore screening performance between DS2017 R2 and DS2018, of a 5-feature pharmacophore against a 50000-compound dataset.
Pharmacophore Mapping
Our 3DEXPERIENCE® platform powers our brand applications, serving 12 industries, and provides a rich portfolio of industry solution experiences. Dassault Systèmes, the 3DEXPERIENCE® Company, provides business and people with virtual universes to imagine sustainable innovations. Its world-leading solutions transform the way products are designed, produced, and supported. Dassault Systèmes’ collaborative solutions foster social innovation, expanding possibilities for the virtual world to improve the real world. The group brings value to over 190,000 customers of all sizes in all industries in more than 140 countries. For more information, visit www.3ds.com.
©20
17 D
assa
ult S
ystè
mes
. All
righ
ts re
serv
ed. 3
DEX
PER
IEN
CE®
, the
Com
pass
icon
and
the
3DS
logo
, CA
TIA
, SO
LID
WO
RKS
, EN
OVI
A, D
ELM
IA, S
IMU
LIA
, GEO
VIA
, EXA
LEA
D, 3
D V
IA, 3
DSW
YM, B
IOVI
A, N
ETVI
BES
, and
3D
EXCI
TE a
re c
omm
erci
al tr
adem
arks
or
regi
ster
ed tr
adem
arks
of D
assa
ult S
ystè
mes
or i
ts s
ubsi
diar
ies
in th
e U
.S. a
nd/o
r oth
er c
ount
ries
. All
othe
r tra
dem
arks
are
ow
ned
by th
eir r
espe
ctiv
e ow
ners
. Use
of a
ny D
assa
ult S
ystè
mes
or i
ts s
ubsi
diar
ies
trad
emar
ks is
sub
ject
to th
eir e
xpre
ss w
ritt
en a
ppro
val.
Dassault Systèmes CorporateDassault Systèmes175 Wyman StreetWaltham, Massachusetts02451-1223USA
BIOVIA Corporate EuropeBIOVIA 334 Cambridge Science Park,Cambridge CB4 0WNEngland
BIOVIA Corporate AmericasBIOVIA 5005 Wateridge Vista Drive,San Diego, CA 92121USA
DS-3054-0118
REFERENCES1. Phillips J.C., Braun R., Wang W., Gumbart J., Tajkhorshid E., Villa E., Chipot C,
Skeel C.D., Kale L., and Schulten K., J. Comp. Chem., 2005, 26, 1781-1802.
2. Brooks B. R., Brooks III C. L., Mackerell A. D., Karplus M., et al, J. Comp. Chem., 2009, 30, 1545-1615.
3. Yesselman J.D., Price D.J., Knight J.L., Brooks III C.L., J. Comput. Chem., 2011, 33(2), 189-202.
4. Roux B., Biophys. J., 1997, 73, 2980–2989.
5. Im W., Beglov D., Roux B., Comput. Phys. Commun., 1998, 111, 59–75.
6. http://qsardb.jrc.it/qmrf/
7. Eswar N., Marti-Renom M. A. Webb B., Madhusudhan M. S., Eramian D., Shen M., Pieper U., Sali A., Current Protocols in Bioinformatics, John Wiley & Sons, Inc., 2006, Supplement 15, 5.6.1-5.6.30.